OMS721 for Patients with IgAN

This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN. MASP-2, is a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. Patients will be involved with the trial for about 2 years, and will take either the study medication or the placebo.

How To Contact a Study Center:

• Visit KidneyHealthGateway.com to see if you might be eligible and to contact a study site near you